Top Suppliers:I want be here
Related CAS#:
181695-72-7 1219794-90-7
1373038-60-8 1189428-23-6
181695-81-8 181696-35-5
501093-54-5 501093-49-8
509074-26-4 1373038-56-2
955117-27-8 1465353-37-0
1465384-17-1 1368383-95-2
1496300-90-3 1782527-70-1
1367927-85-2 1367951-31-2
1369345-79-8 1505923-74-9

181695-72-7

181695-72-7 structure
181695-72-7 structure
  • Name: Valdecoxib
  • Chemical Name: valdecoxib
  • CAS Number: 181695-72-7
  • Molecular Formula: C16H14N2O3S
  • Molecular Weight: 314.359
  • Catalog: Pharmaceutical intermediate API intermediate
  • Create Date: 2018-10-01 12:11:18
  • Modify Date: 2024-01-01 20:35:59
  • Valdecoxib is a highly potent and selective inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.
Name valdecoxib
Synonyms 4-(5-methyl-3-phenylisoxazol-4-yl)benzensulfonamide
Bextra(Valdecoxib)
4-(4-sulfamoylphenyl)-5-methyl-3-phenyl-isoxazole
T5NOJ C1 DR DSZW& ER
4-(5-Methyl-3-phenylisoxazol-4-yl)benzolsulfonamid
Bextra
Valdecoxib
4-[5-methyl-3-phenylisoxazol-4-yl ] benzenesulfonamide
[14C]-Valdecoxib
EINECS 448-010-8
Kudeq
Valdyn
4-(5-Methyl-3-phenyl-1,2-oxazol-4-yl)benzenesulfonamide
4-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide
p-(5-Methyl-3-phenyl-4-isoxazolyl)benzenesulfonamide
4-(5-Methyl-3-phenylisoxazol-4-yl)benzenesulfonamide
MFCD00950568
Valdecoxib(R)
Benzenesulfonamide, 4-(5-methyl-3-phenyl-4-isoxazolyl)-
Description Valdecoxib is a highly potent and selective inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively. Valdecoxib can be used in the research of arthritis and pain.
Related Catalog
Target

COX-2:5 nM (IC50)

COX-1:140 μM (IC50)

In Vitro Valdecoxib (Compound 2) is a highly potent, selective and orally active inhibitor of COX-2, with IC50s of 5 nM and 140 μM for COX-2 and COX-1, respeceively[1]. Valdecoxib (10, 100 µM) inhibits LPS-induced proliferation of endothelial cells and bFGF secretion in a dose-dependent manner. Valdecoxib stimulates VEGF formation via HMEC-1 under inflammatory conditions[2].
In Vivo Valdecoxib (Compound 2) shows potent oral activity in an acute antiinflammatory assay (rat carrageenan foot pad edema; ED50 = 10.2 ± 1.4 mg/kg). Valdecoxib also has chronic antiinflammatory activity in the rat adjuvant arthritis model, with an ED50 of 0.032 ± 0.002 mg/kg/day[1]. Valdecoxib (10 mg/kg, i.p.) significantly attenuates the behavioral and biochemical (oxidative damage) alterations in chronic-stressed mice[3].
Cell Assay HMEC-1 cells proliferation is measured using the MTT conversion method. Cells are seeded (50.000 cells/well) into 96-well plates. The cells are incubated for 24 h with LPS 100 µg/mL, CoCl2 200 µM, Valdecoxib 10 or 100 µM, LPS and Valdecoxib or CoCl2 and Valdecoxib or without tested chemicals (control group). All the substances are added at the same time. After incubation, 50 µL MTT (1 mg/mL) is added and the plates are incubated at 37°C for 4 h. At the end of the experiment, cells are exposed to 100 µL DMSO, which enables the release of the blue reaction product-formazan. The absorbance at 570 nm is read on a microplate reader and results are expressed as a percentage of the absorbance measured in control cells[2].
Animal Admin Mice[3] The drugs including naproxen (14 mg/kg, i.p.), rofecoxib (5 mg/kg, i.p.), meloxicam (5 mg/kg, i.p.), nimesulide (5 mg/kg, i.p.) and Valdecoxib (10 mg/kg, i.p.) are used in the assay. The animals are randomized into 7 groups (n=10 in each group), including the naive group, in which the mice only receive vehicle for 15 d without forced swimming session; the control (chronically stressed) group, in which mice receive vehicle 30 min before the forced swimming session (6 min) for 15 d; the naproxen (14 mg/kg) group; the Valdecoxib (10 mg/kg) group; the rofecoxib (5 mg/kg) group; the meloxicam (5 mg/kg) group; and the nimesulide (5 mg/kg) group. Drugs are suspended in 0.25% carboxymethylcellulose (CMC) and administered intraperitoneally, 30 min before the forced swimming session for 15 consecutive days[3].
References

[1]. Talley JJ, et al. 4-[5-Methyl-3-phenylisoxazol-4-yl]- benzenesulfonamide, valdecoxib: a potent and selective inhibitor of COX-2. J Med Chem. 2000 Mar 9;43(5):775-7.

[2]. Wiktorowska-Owczarek A. The effect of valdecoxib on the production of growth factors evoked by hypoxia and bacterial lipopolysaccharide in HMEC-1 cells. Adv Clin Exp Med. 2013 Nov-Dec;22(6):795-800.

[3]. Kumar A, et al. Protective effects of selective and non-selective cyclooxygenase inhibitors in an animal model of chronic stress. Neurosci Bull. 2010 Feb;26(1):17-27.
Density 1.3±0.1 g/cm3
Boiling Point 481.2±55.0 °C at 760 mmHg
Melting Point 162-164ºC
Molecular Formula C16H14N2O3S
Molecular Weight 314.359
Flash Point 244.8±31.5 °C
Exact Mass 314.072510
PSA 94.57000
LogP 1.71
Vapour Pressure 0.0±1.2 mmHg at 25°C
Index of Refraction 1.609
Storage condition Store at RT
Symbol GHS08 GHS09
GHS08, GHS09
Signal Word Warning
Hazard Statements H361d-H373-H410
Precautionary Statements P273-P281-P501
Hazard Codes Xn,N
Risk Phrases 63-48/22-51/53
Safety Phrases 36/37-61
RIDADR NONH for all modes of transport
HS Code 2935009090
HS Code 2935009090
Summary 2935009090 other sulphonamides VAT:17.0% Tax rebate rate:9.0% Supervision conditions:none MFN tariff:6.5% General tariff:35.0%

Chemsrc provides CAS#:181695-72-7 MSDS, density, melting point, boiling point, structure, formula, molecular weight, synthetic route, etc.
title: CAS No. 181695-72-7 | Chemsrc address: https://www.chemsrc.com/en/baike/1026812.html

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2024 ChemSrc All Rights Reserved